Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

ankylosing spondylitis inflammatory myopathies psoriatic arthritis rheumatoid arthritis sjögren’s syndrome spondyloarthritis systemic lupus erythematosus systemic sclerosis vasculitis

Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
07 2019
Historique:
received: 13 08 2018
revised: 16 11 2018
accepted: 19 01 2019
pubmed: 4 2 2019
medline: 5 3 2020
entrez: 4 2 2019
Statut: ppublish

Résumé

To develop a comprehensive listing of the greatest unmet scientific and clinical needs in rheumatology. The 20th annual international Targeted Therapies meeting brought more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of five disease-specific groups with 20-30 experts assigned to each group based on expertise. Specific groups included rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, connective tissue diseases and a basic science immunology group spanning all of these clinical domains. In each group, experts were asked to consider recent accomplishments within their clinical domain in the last year and update the unmet needs in three categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. While progress was noted among some of previously identified needs, both new needs were identified and themes from prior meetings were re-iterated: the need for better understanding the heterogeneity within each disease, and for identifying preclinical states of disease allowing treatment and prevention of disease in those at risk, and the elusive ability to cure disease. Within the clinical care realm, improved comorbidity management and patient-centred care continue to be unmet needs, and the need for new and affordable therapeutics was highlighted. Unmet needs for new and accessible targeted therapies, disease prevention and ultimately cure remain a priority in rheumatology.

Identifiants

pubmed: 30712015
pii: annrheumdis-2018-214280
doi: 10.1136/annrheumdis-2018-214280
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

872-878

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Auteurs

Kevin L Winthrop (KL)

Oregon Health and Science University, Portland, Oregon, USA winthrop@ohsu.edu.

Michael E Weinblatt (ME)

Brigham and Women's Hospital, Boston, Massachusetts, USA.

Mary K Crow (MK)

Hospital for Special Surgery, New York City, New York, USA.

Gerd R Burmester (GR)

Charité-Universitätsmedizin Berlin, Berlin, Germany.

Philip J Mease (PJ)

Swedish Medical Center, University of Washington, Seattle, Washington, USA.

Alexander K So (AK)

University of Lausanne, Lausanne, Switzerland.

Vivian Bykerk (V)

Hospital for Special Surgery, New York City, New York, USA.

Ronald F Van Vollenhoven (RF)

Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands.

Maxime Dougados (M)

Hôpital Cochin, Paris, France.

Jonathan Kay (J)

University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Xavier Mariette (X)

Paris-Sud University, Orsay, France.

Joachim Sieper (J)

Department of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.

Fritz Melchers (F)

Max Planck Institute for Infection Biology, Berlin, Germany.
Deutsches Rheumaforschungszentrum, Berlin, Germany.

Bruce N Cronstein (BN)

NYU School of Medicine, New York City, New York, USA.

Ethan Shevach (E)

National Institutes of Health, Bethesda, Maryland, USA.

Ferdinand C Breedfeld (FC)

Leiden University Medical Center, Leiden, Netherlands.

Joachim Kalden (J)

University of Erlangen, Erlangen, Germany.

Josef S Smolen (JS)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

Daniel E Furst (DE)

Swedish Medical Center, University of Washington, Seattle, Washington, USA.
Los Angeles Medical Center, University of California, Los Angeles, California, USA.
University of Florence, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH